[{"orgOrder":0,"company":"TearSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Series B Financing","leadProduct":"Lacritin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"TearSolutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"TearSolutions \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"TearSolutions \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by TearSolutions

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The proceeds will accelerate company's programs for rare corneal diseases at preclinical and clinical stages, including Lacripep, derived from the Lacritin protein, a first-in-class topical therapy.

                          Brand Name : Lacripep

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          November 21, 2024

                          Lead Product(s) : Lacritin

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : $3.0 million

                          Deal Type : Series B Financing

                          blank